Phase IIb trial investigating the efficacy of KRN 5500 in patients with chronic chemotherapy-induced neuropathic pain.
Phase of Trial: Phase II
Latest Information Update: 29 Nov 2012
At a glance
- Drugs KRN 5500 (Primary)
- Indications Neuropathic pain
- Focus Therapeutic Use
- 18 Jan 2012 Planned initiation date changed from 1 Jul 2010 to 1 Jun 2012.
- 25 Mar 2010 This trial is expected to be initiated in the second half of 2010 according to a Dara BioScience media release.
- 27 Nov 2009 New trial record.